Have any questions? 706-721-6582 or cts@augusta.edu
- ONO-7475-01: A Phase I/II open label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical efficacy of ONO-7475 in patients with acute leukemias or myelodysplastic syndromes
Clinical Trial
ONO-7475-01: A Phase I/II open label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical efficacy of ONO-7475 in patients with acute leukemias or myelodysplastic syndromes
This is a research study to test a new drug called ONO-7475 that is not approved by the Food and Drug Administration (FDA), in combination with venetoclax, to treat Acute Myeloid Leukemia (AML) that has come back or has not responded to treatment. We are looking to see if the drug works on your cancer and if the drug is safe. Venetoclax is approved by the FDA for the treatment of certain blood cancers, such as chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and newly diagnosed AML patients. The combination of ONO-7475 with Venetoclax is investigational.
Eligibility Criteria
- Male or female, aged 18 years or older Subjects with confirmed Acute Myeloid Leukemia (AML) that has come back or has not responded to treatment Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
RESEARCH. INNOVATION. DISCOVERY.